Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD

Abstract

Abstract Mitogen-activated protein kinase p38 is a key regulator in the inflammation pathway and is activated in the lungs of chronic obstructive pulmonary disease (COPD) patients. Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD). In this Phase II, double-blind, randomized, placebo-controlled dose-exploration study of acumapimod in patients with moderate or severe AECOPD (NCT01332097), patients presenting with AECOPD were randomized to receive single-dose acumapimod (20\u2009mg or 75\u2009mg) on Day 1, repeated single-dose acumapimod (20\u2009mg or 75\u2009mg) on Days 1 and 6, oral prednisone 40\u2009mg (10\u2009days), or placebo. Primary outcome: improvement in forced expiratory volume in 1\u2009s (FEV1) versus placebo at Day 5 (single doses) and Day 10 (repeated doses). N\u2009=\u2009183 patients were randomized; 169 (92%) patients completed the study. Although the primary endpoint (FEV1 at Day 10) was not met (p\u2009=\u20090.082), there was a significant improvement in FEV1 with acumapimod repeat-dose 75\u2009mg versus placebo at Day 8 (p\u2009=\u20090.022) which, though not a prespecified endpoint, was part of an overall trend. Differences at lower doses did not achieve significance. Mean change in FEV1 AUC from baseline to Day 14 in the 75\u2009mg repeat-dose group was significantly higher versus placebo (p\u2009=\u20090.02), prednisone (p\u2009=\u20090.01), and 20\u2009mg single-dose groups (p\u2009=\u20090.015) (post-hoc analysis). EXACT-PRO showed numerical differences versus placebo that did not reach significance. Acumapimod was well tolerated. In conclusion, repeated single-dose acumapimod showed a clinically relevant improvement in FEV1 over placebo at Day 8, along with consistent numerical differences in EXACT-PRO. These data can be used to determine dose regimens for a proof-of-clinical-concept trial.